Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients

Inclusion Criteria: * confirmed Richter's transformation in treatment naïve and previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma patients * may have had prior exposure to ibrutinib and other B-cell signaling receptor agents * Adequate hematologic function * Adequate liver and kidney function * Willing and able to participate in all required evaluations and procedures in this study protocol * Female subjects of childbearing potential must not be pregnant upon study entry * Male and female subjects who agree to use highly effective methods of birth control Exclusion Criteria: * known allergy to any of medications * chemotherapy taken within 21 days of study treatment * targeted therapy within 10 days of study treatment * BCR inhibitors within 24 hours of study treatment * major surgery within 4 weeks of first dose of study treatment * women who are pregnant * known infection with HIV or Hepatitis C * Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug